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1.1. Cervical intraepithelial neoplasia  
In the late 1960s, a number of studies on precancerous lesions of the cervix suggested that 
the cellular changes of dysplasia and carcinoma in situ were qualitatively similar and 
remained constant throughout the histologic spectrum. Both dysplasia and carcinoma in 
situ were found to be monoclonal proliferations of abnormal squamous epithelial cells with 
an aneuploid nuclear DNA content. On the basis of these descriptive biological studies, 
Richart introduced the concept that all types of precursor lesions to squamous cell 
carcinoma of cervix represented a single disease process, which he termed cervical 
intraepithelial neoplasia (CIN) (Richart RM, 1973).  
CIN is predominantly a disease of women in their reproductive years, with a large 
population impact and risk factors characteristic of a sexually transmitted disease.  
The prevalence of CIN has increased during the last decades, especially among younger 
women. Currently the age specific incidence for CIN peaks in the 25-29 years old group 
and decreases with age thereafter (Bosch et al, 1995). Another large national program that 
compiles statistics of cytologic abnormalities among women in the United States was 
performed. This program is designed to increase access to cancer screening for low-income 
and uninsured women. The prevalence of cytologically detected CIN among women 
enrolled decreases with increasing age (Lawson et al., 1998) (Fig. 1). 
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Fig. 1. Impact of age on the prevalence of biopsy-confirmed cervical lesions. Data from the National 
Breast and Cervical Cancer Early Detection Program demonstrates a reduction in the prevalence of both 
low-grade CIN and high-grade CIN with increasing age. The prevalence of invasive cervical cancer 




1.2. Human papillomavirus and CIN 
A large number of epidemiologic, clinicopathologic, and molecular studies have 
subsequently linked the presence of specific types of human papillomavirus (HPV) to the 
development of anogenital cancers and their precursors, and it is now accepted that HPVs 
play a critical role in the pathogenesis of most cervical cancers and CIN lesions (Munoz, 
2000).  
Human papillomavirus (HPV) is a DNA virus with a small genome of 7.9 kilobase pairs 
(kb) that infect epithelial cells (Fig. 2). About 70 different genotypes have been identified 
to date. Some HPV types (e.g. HPV 6 and 11) are mainly detected in genital warts, flat 
condylomata, and low grade intraepithelial neoplasias whereas others (e.g., HPV 16 and 18) 
are frequently associated with severe intraepithelial neoplasia and invasive cancer, leading 
to the concept of two groups of HPV, low risk HPV and high risk HPV (HR-HPV).  
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Fig. 2. Genome organization of HPV 16 deduced from the DNA sequence. 
 
 
Although the HPV life cycle is not completely characterized, the rough outlines of the 
process are known (Fig. 3). The initial site of infection is thought to be either basal cells or 
primitive “basal-like” cells of the immature squamous epithelium, which may result from 
the presence of specific receptors for HPV on the basal cells. One potential receptor that 
has been localized to the basal cells complexes containing alpha6 integrin complexed with 
either beta 1 or beta 2 integrins (Evander et al., 1997). Once HPV enters into the basal cells, 
it can exist within the cells in two distinct biologic states. One is as a nonproductive 
infection in which HPV DNA continues to reside in the basal cells but infectious virions 
are not produced. In the literature, nonproductive HPV infections have frequently been 
referred to as latent infections. In non-productive latent infections, a small number of 
copies of the HPV genome usually remain in the nucleus in a free circular form called an 
episome. Replication of the episomal DNA in latent infections is tightly coupled to the 
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replication of the epithelial cells and only occurs in concert with replication of the host cell 
chromosomal DNA. The other form of HPV infection is a productive viral infection. In 
productive viral infections, viral DNA replication occurs independently of host 
chromosomal DNA synthesis. This independent viral DNA replication produces large 
amounts of viral DNA and results in infectious virions. Viral DNA replication takes place 
predominantly in the intermediate and superficial cell layers of the stratified squamous 
epithelium. As the virally infected epithelial cells mature and move toward the epithelial 
surface, cell-derived, differentiation-specific transcriptional factors produced by the 
epithelium stimulate the production of viral capsid proteins. This process allows large 
amounts of intact virions to be formed and produces the characteristic cytopathic effects of 
HPV that can be detected cytologically and histologically. These cytopathic effects include 









    
 
Fig. 3. Lifecycle of HPV The first step in an HPV infection is contact of intact virions with 
basal cells or immature squamous metaplastic cells. This can produce either a 
non-productive infection or productive infection. In a non-productive infection HPV DNA 
remains as an episomal form in the nucleus of the infected vassal cell. In productive 
infections, viral replication becomes uncoupled from cellular DNA synthesis and large 
amounts of viral DNA and proteins are made in the intermediate and superficial cell layers 
of the epithelium, producing the characteristic cytopathic effects of HPV. During the 
development of high-grade squamous intraepithelial lesion (SIL) and invasive squamous 
cancers, additional cellular and viral events take place resulting in the formation of a “true” 
cancer precursor. These can include the generation of aneuploid stemlines and integration 




Molecular studies using tissue culture cells have provided insight into the mechanism by 
which HPV malignant transforms in cervical epithelium (McDougall, 1994). Substantial 
evidence has been accumulated demonstrating the requirement for viral oncogene 
expression in order to maintain the immortalized state in high risk HPV-DNA carrying 
cells (zur Hausen, 1996). HR-HPV such as HPV16 and 18 produce three proteins with 
growth-stimulating and transforming proteins, E5, E6 and E7. E5 is not essential for 
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transformation as the E5 region is frequently deleted in cervical carcinoma cells (Schwarz 
et al, 1985). However, E6 and E7 are consistently expressed in more than 90% of cervical 
cancers (zur Hausen, 1991). Mutational analysis of E6 and E7 indicates that the capacity to 
bind Rb and p53, respectively, is important for the transforming and immortalizing 
function of these oncoproteins (Hollingworth et al, 1991). Both E6 and E7 play important 
roles in productive viral infection and the life cycle of HPV. During the viral life cycle, 
E2-derived proteins act as important regulators of the expression of the E6 and E7 open 
reading frames (ORFs) (Ustav et al, 1998). In most infected epithelia, E2 appears to inhibit 
transcription from the E6 and E7 ORFs, which helps maintains some regulation of cellular 
proliferation. In most low-grade cervical cancer precursor lesions, HPV DNA exists as 
episome. In the episomal form, the E2 ORF is physically intact, and transcription from the 
E6 and E7 ORFs is presumed to be well regulated. However, in some high-grade precursor 
lesions, 75% of HPV16- and almost all HPV18-associated carcinomas, the HPV genome 
becomes physically integrated into the host chromosomal DNA (Cullen et al, 1991). 
Integration into the host chromosomal DNA appears to be a random event that does not 
lead to the consistent activation of specific cellular oncogenes. However, integration 
requires that the episomal viral genome breaks, and this break frequently leads to 
disruption of the E2 ORF (Choo et al, 1987). Disruption of the E2 ORF with retention of 
the E6 and E7 ORFs could result in the unregulated expression of the E6 and E7 






1.3. Management of CIN 
Numerous approaches have been suggested for treating CIN with satisfactory efficacy. 
Standard treatment includes excision techniques, such as cold knife conization or loop 
electrosurgical excision. These procedures have the advantage of providing an evaluable 
pathological specimen, being, however, commonly associated with post-operative bleeding. 
Destructive techniques, such as cryotherapy and laser ablation, frequently suffer from 
unsatisfactory post-operative colposcopy or, for the latter, increased costs. All methods 
involve a substantial destruction of the cervical stroma, which may lead to scar stricture 
with increased risk of infertility and necessity of subsequent cesarean section or, adversely, 
cervical incompetence with premature deliveries and low-birth-weight babies (Bigrigg et 
al., 1991; Luesley et al.,1985). 5-Aminolaevulinic acid (ALA)-mediated photodynamic 
therapy provides an alternative therapy avoiding complications like post-operative 
bleeding, cervical stenosis with consequent infertility and cervical incompetence leading to 
premature deliveries and low birth weight, respectively (Mathevet et al, 2003).   
 
1.4. Photodynamic therapy and diagnosis (PDT, PDD) 
Photodynamic therapy (PDT) is an investigational strategy for cancer therapy. It consists of 
the administration of an exogenous photoactivable compound that accumulates in 
malignant and other hyperproliferating tissues, followed by an adequate dose of 
photoactivating light. It is thought to operate via the generation of highly reactive oxygen 
species that induce tumour necrosis by direct cytotoxicity and /or by indirect effects 
mediated via collapse of the tumour vascular supply (Henderso et al.,1992; Stewart et al., 
1998). Photofrin, a mixture of porphyrin, is the photosensitizer that has been used in the 
majority of clinical trials (Dougherty, 1987; Marcus, 1992). However, prolonged skin 
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photosensitivity due to non-specific localisation of the photosensitizers is associated with 
Photofrin-mediated PDT (Benson, 1988). Therefore new photosensitizers and better 
methods of photosensitizer localisation are being investigated (Bachor et al., 1991; Goff et 
al., 1991). Other approaches for achieving better localisation include local administration 
of the photosensitizer (Amano et al., 1988; Bachor et al., 1992). 
In the last decade much interest has been focused on a different approach to PDT in which 
a precursor, 5-ALA (Fig. 4A), is administered and synthesis of the photosensitizer, 
Protoporphyrin IX (PPIX) (Fig. 4B), accomplished in situ (Kennedy, 1990; Loh, 1993; 
Svanberg, 1994, Peng et al, 1997 ). In most clinical and preclinical studies systemic or 
topical application of 5-ALA is used to temporarily increase the accumulation of 
porphyrins, i. e., in particular PPIX in the target tissue. 5-ALA is a precursor of heme 
formed by 5-ALA- synthase from glycine and succinyl-CoA, the rate limiting step of the 
heme biosynthesis (Fig. 5, 6). Once this step is bypassed by exogenous administration of 
5-ALA, formation and accumulation of PPIX preferentially takes place in tissues known 
for high cellular turnover. The main reason why PPIX accumulates with some degree of 
selectivity is still unknown. In some tumors, however, ferrochelatase activity is reduced, 
which forms heme by incorporation iron into PPIX (Kondo et al, 1993). 5-ALA-induces 
porphyrins are cleared from the skin within 24 – 48 hours of topical, systemic, or 
intradermal administration. Inconvenience of the patient is minimized, e. g. by shielding 
against exposure of light. 
To date 5-ALA-induced fluorescence has been successfully employed in diagnosis and 
treatment of various premalignant and malignant diseases. As a given condition for both 
techniques photoreactive drugs accumulate mainly in tumors and other hyperproliferating 
tissues such as dysplastic lesions. Light induced fluorescence can then be used to detect 
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CIN lesions and e. g. serve as a guide for the surgeon to resect malignant tissues (Stummer 
et al, 2000) or help to diagnose CIN without the requirement of an extensive training as a 
colposcopist. Furthermore after application of a photosensitizer light induced fluorescence 
renders dysplastic cell susceptible to destruction by laserlight of a certain wavelength 
mediated by local cytotoxic effects of reactive oxygen species, in particular, singlet oxygen. 
The short half-life of such cytotoxic species, the tissue selectivity of the photosensitizer 
and the laser irradiation restricted to the tumour area ensures that phototoxic damage 
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Fig. 5. Simplified biosynthetic pathway for heme. Fluorescing and photosensitizing compounds are 
highlighted, with bigger protoporphyrin Ⅸ highlighted. The 5-aminolevulinic acid/heme feedback 
control is indicated by a blue arrow. The principal biosynthetic route for ALA-induced protoporphyrin 






























Photodynamic diagnosis (PDD) is the method of choice for the endoscopic detection of  
preneoplastic and neoplastic lesions of the urinary bladder (Zaak et al, 2002) and has been 
proven to be a reliable tool for the detection of low and high grade dysplasia in Barrett´s 
oesophagus, melanoma, oral and laryngeal cancer, and early stage lung cancer (Endlicher 
et al, 2001, Pahernik et al, 2001, Leunig et al, 2002, Baumgartner et al, 1996). Furthermore 
5-ALA induced fluorescence is useful in guided resection of tumors, such as glioblastoma 
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1.5. Aim of the study 
 
For CIN lesions studies showed equivocal outcomes. Although Hillemanns et al could 
verify specific porphyrin fluorescence of CIN after local administration of 1 % aqueous 
solution of 5-ALA (Hillemanns et al 2000), photodynamic therapy after topical application 
of 3% 5-ALA in Intrasite Gel was not successful in the treatment of CIN (Barnett et al, 
2002). In contrast in another study PDT with 5-ALA applied to the cervix as a 12 % watery 
solution was efficient in improving the grading of the PAP smears in 19 of 20 CIN patients 
and in eradication of cervical HPV-Infection in 80 % (Wierrani et al, 1999). These 
contradictory results suggest that the outcome of PDD and PDT depends on various 
factors.  
 
Esterified derivatives of ALA that increase its lipophilicity, such as methyl-ALA, 
butyl-ALA and hexyl-ALA, could potentially enhance efficacy. Xiang et al. confirmed that 
hexyl-ALA penetrates across biological barriers of cervical carcinoma cell lines in a 
significantly faster manner, generated an obvious higher formation of PPIX and induced 
the highest level of phototoxicity compared to 5-ALA or other ALA-ester (Xiang et al., 
2001). In non lesional skin, equimolar concentrations of the hexyl and pentyl ester, but not 
butyl ester, promote higher PPIX levels and greater PPIX-induced phototoxicity than ALA 
(Gerscher et al, 2000; Gerscher et al, 2001). 
 
Thermogel is a thermolabile bioadhesive gel which consist of Lutrol F-127 (poloxamer 
407). The significant character of thermogel is the temperature dependant viscosity. It is of 
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liquid state at 4°C and turn into viscous gel state at more than 30°C. It is easy to handle 
and proofed reliable as vehicle carrier for the application to cervix (Andikyan et al, 2004). 
 
In order to obtain basic clinical data for the further development of PDD and PDT, we 
investigated the pharmacokinetics and the tissue selectivity of topically applied 
ALA–induced porphyrins from hexyl-ALA-thermogel in patients with CIN lesions by in 



















2. Materials and Methods 
 
2.1 Patients 
Our study was approved by the ethics committee of our institution, and informed consent 
was obtained from all women enrolled. Twenty-four non-pregnant women with a mean age 
of 39 years (range 22 - 47 years) with a cytological diagnosis of high grade or permanent 
low grade squamous intra-epithelial lesions were included. Each patient had a complete 
history and gynecologic examination taken including cervical cytology, HPV DNA testing, 
colposcopy and biopsy. Tissue biopsies were obtained according to colposcopy. H&E 
staining of the final conization specimens showed CIN 1 in 9 cases, CIN 2 in 8 cases, and 
CIN 3 in 7 cases (Fig. 7). In one case, the specimen taken for the study measurements was 
not satisfactory, containing only endocervical glands (histology showed CIN 3 of the  













2.2. HPV detection 
Specimens were tested for HPV DNA by the Food and Drug Administration (FDA) 
approved Hybrid Capture 2 HPV DNA assay (Digene, Silver Spring, MD) and analyzed 
for the presence of low risk HPV types 6, 11, 42, 43, and 44 and high risk HPV types 16, 
18, 31, 33, 35, 45, 51, 52 and 56. The hybrid capture system is a capture molecular 
hybridization assay that uses chemoluminescence detection in tubes. Samples were 
classified positive for HPV DNA if the relative light-unit reading obtained from the 
luminometer was equal to or greater than the mean of positive control values according to 
the instructions by the manufacturer. One woman was negative for HPV DNA, whereas 
one harboured only low risk type viruses, 22 harboured high risk type viruses, and one 
























2.3. Hexyl-ALA-thermogel preparation and administration 
Thermogel was supplied as powder by Biolitec GmbH (Jena, Germany). 19% thermogel 
was made dissolving Lutrol F-127 powder in sterile water and stored at 4°C. 4mmol (mM) 
and 10mM hexyl-ALA-thermogel were freshly prepared before application at 4°C. Ten 
millilitres of  hexyl-ALA-thermogel in concentrations of 4 mM (12 patients), 10 mM (12 
patients) were topically applied to the cervix for 5 to 720 minutes.  
 
2.4. Fluorescence imaging for CIN lesions  
Prior to surgical conization, the fluorescence video image analysis was performed using a 
special equipment for semiquantitative fluorescence video image analysis of ALA-induced 
porphyrin (Fig. 9). It was performed under violet light (D-LIGHT) by looking through a 
modified endoscope (Fig. 10). Visual observation of the fluorescence images was possible 
with the naked eye. For documentation, a sensitive color charge coupled device camera 
was attached to the endoscope. A specific red PPIX fluorescence of the CIN lesions 
corresponding to the acetowhite colposcopic pattern with mosaicism was observed after an 






























 Fig. 9. Complete equipment for fluorescence endoscope with ALA 
The standard equipment includes D-LIGHT System and fluorescence-capable    
endoscopes (KARL STORZ GmbH). Video documentation additionally requires: 
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Fig. 10. Scheme of the fluorescence imaging and spectroscopic system used for 
fluorescence photodetection of cervical lesions after topical application of ALA. 











2.5. Fluorescence microscopy for CIN tissues 
Excised tissues were forwarded for routine diagnostic evaluation, while a segment of the 
resected tissue (conization specimens) was deep frozen at –80°C for quantitative 
fluorescence measurements. Samples were cut under reduced ambient light into serial 
cryosections for histological evaluation (6 µm thickness; staining with haematoxylin and 
eosin) and for quantitative fluorescence microscopy (15 µm thickness).  
 
All procedures were carried out under reduced ambient light to minimize photodegradation 
of porphyrins. On a microscope with epifluorescence and transillumination facilities 
(Orthoplan; Leitz, Wetzlar, Germany), images from identical areas (magnification 10X) 
were taken by a Three-Chip-CCD camera with an integration mode which was developed 
for the purpose of fluorescence documentation (Tricam SL PAL PDD, K. Storz, Tuttlingen, 
Germany) (Fig. 11). This set-up allowed us to depict two different images from identical 
areas in one tissue section at a high spatial resolution, one by transillumination for 
determining regions of interest (ROI) for specific tissue types and one by fluorescence 
microscopy for quantifying fluorescence with a high light sensitivity. A 100 Watt mercury 
light source was used to excite porphyrins by a wavelength of 355 to 425 nm. Fluorescence 
emission was detected above 610 nm. Transillumination and fluorescence images were 
digitized and analyzed by an image analysis system (Optimas 6.2, Media Cybernetics, 
Silver Spring, MD, USA). For measurements, the regions of interest (ROI) in dysplastic 
squamous epithelium and normal tissue were identified from sequential histological 
sections stained with hematoxylin and eosin, defined in the transilluminated picture, and 
the respective fluorescence intensity was quantified in the fluorescence image. 
In each specimen, fluorescence was quantified in defined ROIs (as mentioned above) of 
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dysplastic and normal squamous epithelium as well as of subepithelial stroma and some 
specimens of cervical glands.  
Squamous epithelium was divided into three layers: 
- lower layer: basal and parabasal cells 
- middle layer: intermediate cells 
- upper layer: superficial cells 
Because of the heterogenous morphology of particularly the dysplastic epithelium we 
quantified the intensity of PPIX fluorescence in the corresponding layer of normal and 
dysplastic squamous epithelium. 
The contrast of red PPIX fluorescence to green autofluorescence was divided into four 
degrees:  
• no fluorescence        (0 point)  
• little fluorescence     (1 point) 
• moderate fluorescence  (2 points)  
• strong fluorescence     (3 points) 
Quantitative spectroscopy was performed at a wavelength of 635 nm for PPIX 
fluorescence and at 600 nm for autofluorescence using an optic multi-channel-analyzer 
(Princeton Instruments, Trenton, NJ, USA), which was connected to the camera by a fiber. 







Fig. 11. Scheme of the fluorescence microscope and imaging system used for    




2.6. Statistical analysis 
Statistical analysis was performed using the Student-t-Test. P-values < 0.05 were regarded 









3.1. Fluorescence imaging for CIN 
The modified endoscope proved to be applicable for real-time and non-invasive 
fluorescence imaging of ALA- induced PPIX of the ectocervix in 24 CIN patients. The red 
fluorescence could be studied either directly by looking through the endoscope or on a 
video monitor via an attached color endocamera. During endoscopic evaluation of the 
portio uteri and the vagina, switching of camera and light modes between blue light for 
fluorescence detection and normal white light was easy to perform and did not hinder the 
procedure. 
Using an optimal time frame of 100-540 minutes between hexyl-ALA application and 
fluorescent detection, we observed a specific red PPIX fluorescence of the CIN lesions 
corresponding to the acetowhite colposcopic pattern with mosaicism (Fig. 12).  
 
 
Fig. 12. Colposcopy of a CIN 2 lesion at the posterior lip of the ectocervix representing 
acetowhiteness and mosaicism is shown. Correspondingly, the red 
hexyl-ALA-induced PPIX fluorescence of the same lesions is clearly distinct from 
the background of the greenish autofluorescence of the normal cervical tissue. 
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3.2. Time course of PPIX fluorescence intensity in normal and dysplastic epithelium 
 after topical application of hexyl-ALA  
All of the specimens were obtained from the surgical conization tissues of CIN patients. 
One patient was evaluated at one time point in our study. 
 
According to data from our in vitro study (Xiang et al., 2001), it was assumed that uptake 
and conversion of hexyl-ALA to PPIX requires a short time interval. Therefore, we 
proposed in this feasibility study a short incubation of hexyl-ALA with time intervals from 
5 minutes to 100 minutes for both concentration 4 mM and 10 mM. After the assessment 
of fluorescence microscopy in the conization resections, rather low fluorescence intensity 
values were detected. Therefore, longer incubation intervals had to be evaluated. However, 
time intervals of 300 to 500 minutes are clinically difficult because the conization surgery 
is performed in the morning and the application should be done between midnight and 
morning. 
 
The histological evaluation of the 24 specimens revealed CIN 1-3 in 23 cases, however, in 
one specimen (4 mM hexyl-ALA) no squamous epithelium could be seen. By means of 
fluorescence microscopy, the hexyl-ALA induced PPIX fluorescence intensity was 
measured both in dysplastic and adjacent normal epithelium of the 11 specimens with 4 
mM hexyl-ALA and 12 specimens with 10 mM hexyl-ALA. The spectroscopic 
measurement were performed three times for one specimen. The mean of the measurement 
was displayed in the figures. The time course of the intensity of porphyrin fluorescence in 
23 patients with 4 mM and 10 mM hexy-ALA is shown in Figure 13 A-B. 
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In both dysplastic and normal adjacent epithelium fluorescence intensity increased with 
time of exposition. Up to sixty minutes nearly no fluorescence could be detected. Then the 
fluorescence intensity rose and reached a peak between 180 to 540 minutes. After an 
application time of 540 minutes, the fluorescence intensity seemed to decline again. 
However, due to limited data of the long incubation intervals this remains speculative. 
Time-dependency of fluorescence intensity showed the same kinetics in normal epithelium 
and CIN lesions. However the peak between 180 to 540 minutes was much more 
pronounced in dysplastic epithelium just as the absolute fluorescence intensity was 




























































The fluorescence pattern was homogeneous along the horizontal dimension of the tissue 
section. There was no such irregularities noted as compared to our first study employing 
3% 5-ALA without Lutrol F-127 thermolabile gel as carrier (Pahernik et al, 1998).  
 
3.3. Selectivity of PPIX fluorescence for CIN 
Mean fluorescence intensity of 23 specimens with 4 mM and 10 mM hexyl-ALA was 1484 
+ 263 calibrated units (c.u.) for normal epithelium and 2342 + 381 c.u. for CIN of different 
grades. This difference is statistically significant (p<0.05) (Fig. 14). The mean 
fluorescence intensity of the 9 cases with CIN 1, the 8 cases with CIN 2 and of the 6 cases 
with CIN 3 were 2052 + 361 c.u., 2516 + 147 c.u. and 2546 + 353 c.u., respectively (Fig. 
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15). Comparing the mean fluorescence intensity of high and low grade CIN no statistical 
difference could be found.  
 
Tumour selectivity which is a preferred parameter for PDD and to a certain extent also for 
PDT was defined as the ratio of dysplastic vs. adjacent normal epithelium in 23 specimens. 
According to the regression curve set through the measured fluorescence data the tumor 
selectively for CIN showed a peak of 1.8 after 240 to 420 minutes, gradually decreasing 
afterwards to a ratio of 1 after 600 to 720 minutes (Fig. 16). However, it has to be stressed 
that this is an assumption based on only few long term incubation data. 
 
 
Fig. 14. Mean PPIX fluorescence intensity in normal  squamous epithelium and CIN  























































































3.4. Influence of hexyl-ALA concentration on fluorescence intensity 
PPIX fluorescence intensity after administration of 4mM (11 cases) and 10mM (12 cases) 
concentration of hexyl-ALA were 2294 + 175 c.u. and 2386 + 463 c.u. in CIN 1-3, 
respectively (Fig. 17). It did not reach statistical significant but the PPIX fluorescence 
intensity was more stable and higher after application of 10mM hexyl-ALA (Fig. 18).  
 
 
Fig. 17. Mean PPIX fluorescence intensity in 4mM hexyl-ALA and 10mM hexyl-ALA 


















































Fig. 18. The PPIX fluorescence intensity after application of 10mM hexyl-ALA 
        in CIN 1-3 
 
3.5. Topographical fluorescence assessment by microscopy 
Table 1. shows the results of a semi-quantitative evaluation of fluorescence intensity by 
microscopy in 23 CIN patients. 
Maximum intensity could generally be detected in the lower layer of the epithelium, 
consisting of basal and parabasal cells. Fluorescence intensity gradually declined from the 
basal membrane to the surface of the epithelium (Fig. 19, 20). The fluorescence intensities 
of the lower layer is much higher than in the upper layer (p< 0.05), but not significantly 
higher than in the intermediate layer (p>0.05). This applies to normal and dysplastic 
epithelium. In CIN lesions PPIX fluorescence intensity (mean 5.2 ± 0,88) was higher than 
in normal epithelium (mean 3.45 ± 0,4). This difference is statistically significant (p<0.05). 
The fluorescence intensities of between lower, intermediate and upper layers of CIN 




Table 1: Mean PPIX-fluorescence intensity in semiquantitative, topographic fluorescence 









Fluorescence in  
upper 
layer 
Negativ 3,45+0,4 1,5 1,25 0,7 











     Fig. 19A. Topographical fluorescence. Strong fluorescence in the  
             squamous epithelia of CIN3 (x 100)  
 
 
              







     Fig. 20A. Topographical fluorescence. Moderate fluorescence in the 





              
         Fig. 20B. Histopathologic findings of patient 20A (H&E, x 100) 
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4. Discussion 
Topical ALA induced endogenous photosensitisation seems to be a very promising 
approach for selective PDT and has been used clinically for various diseases. A great 
advantage of topical PDT compared with systemic photosensitizers like photofrin is the 
rapid clearance of protoporphyrin and ALA from the skin. In addition, compared to 
systemic application of ALA, after its topical administration no significantly increased 
porphyrin levels in plasma were detected. Systemic ALA administration might cause liver 
damage as well as neuropsychiatric disorders similar to symptoms of acute intermittent 
porphyria (Regula et al, 1995). 
 
Up to now, only a few studies have been performed with respect to the pharmacokinetics 
of ALA- induced porphyrins following topically application using various administration 
modalities and dosages. This study was designed to obtain more information about 
pharmacokinetics and selectivity about 5-ALA induced PPIX fluorescence from  
hexyl-ALA as a basis for porphyrin mediated diagnosis and therapy of CIN.  
 
To date several studies investigated concentration-dependency of 5-ALA-induced 
fluorescence in vitro (Rossi et al, 1996; Fukuda et al, 1993). Fukuda et al. cultured 
mammalian epithelial cells (CNCM-I-221) and Rossi et al. cultured various gynaecological 
tumour cell lines ( HeLa, SiHa, MDA-MB-231, A2780-9S, 2780AD ) with 5-ALA. They all 
could find a stagnation of fluorescence with rising concentration. This saturation may be 
attributed to a limited uptake of 5-ALA or a limited conversion to PPIX (Iinuma et al, 
1994). Our group demonstrated that hexyl-ALA penetrates across biological barriers of 
cervical carcinoma cell lines in a significantly faster manner, generated a obviously higher 
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formation of PPIX and induced the highest level of phototoxicity compared to 5-ALA or 
other ALA-ester (Xiang et al., 2001). Recently, a clinical investigation with hexyl-ALA 
has shown that hexyl-ALA induced fluorescence can be used for photodynamic diagnosis 
(PDD) in human bladder cancer. They applied 4 to 16 mM hexyl-ALA to assess the 
feasibility and the advantages of a topical ALA ester-based fluorescence photodetection in 
the human bladder. The results shown that the application of 8 mM hexyl-ALA could 
provide sufficient PPIX fluorescence for reliable photodetection of malignant and 
pre-malignant lesions. The PPIX fluorescence intensity reached a twofold increase using 
20-fold lower concentrations as compared to ALA (Lange et al, 1999). Furthermore, Marti 
et al demonstrated that hexyl-ALA could lead to a homogenous distribution of PPIX 
fluorescence in pig bladder model (Marti et al, 1999). Therefore, we applied two different 
concentrations of hexyl-ALA (4mM and 10mM) to the cervix in order to identify the 
required concentration to reach the highest fluorescence intensity.  Fluorescence intensity 
was highest after application of 10mM hexyl-ALA but we could not find a statistical 
difference in the fluorescence intensity achieved by different hexyl-ALA-concentrations. 
However, the hexyl-ALA induced fluorescence was longer stable at 10mmol compared to 
4 mmol which may be relevant to extended cytotoxic effects. Consequently, we 
recommend the use of 10mM hexyl-ALA for PDT. 
 
We also investigated the time course of PPIX fluorescence and found for CIN-lesions an 
increased porphyrin fluorescence peak beyond 200 minutes. Up to sixty minutes nearly no 
fluorescence could be detected. Then the fluorescence intensity rose and reached a peak 
between 180 to 540 minutes. After an application time of 540 minutes, the fluorescence 
intensity seemed to decline again. However, due to limited data of the long incubation 
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intervals this remains speculative. Our results are concordant to other investigations 
showing a peak fluorescence intensity after 4 to 7 hours depending on the mode of 
application (Ash et al, 1993). Based on these data we recommend an exposition-time of 
more than 200 minutes. 
 
A statistically significant difference in PPIX fluorescence intensity was found between 
CIN (2342+381 c.u.) and normal surrounding squamous epithelium (1484+263 c.u.) 
(p<0.05). Furthermore, we could also observe a clear contrast between CIN tissue and 
normal surrounding epithelium. This so called dysplastic cell selectivity was defined as 
ratio of fluorescence intensity in CIN areas vs. fluorescence intensity in normal tissue. For 
PDT high dysplastic cell selectivity means an optimum therapeutic effect with minimum 
destruction of normal tissue. Kinetics showed that dysplastic cell selectivity was best 
between 60 and 200 minutes according to raw data. According to the regression curve set 
through the measured fluorescence data the tumor selectivity for CIN showed a peak of 1.8 
after 240 to 420 minutes, gradually decreasing afterwards to a ratio of 1 after 600 to 720 
minutes. However, it has to be stressed this is an assumption based on only few long term 
incubation data. The highest measured selectivity between 60 and 200 minutes in this 
fluorescence microscopy study corresponds to clinical data using fluorescence diagnosis 
and spectroscopy of patients . Longer time intervals reached a lower selectivity, but higher 
fluorescence (Hillemans et al, 2000). 
 
Compared to our previous 5-ALA- induced porphyrin fluorescence microscopy study, we 
achieved improved results with hexyl-ALA (Andikyan et al, 2004) (Tab. 2). The maximum 
fluorescence derived from the extrapolated curve (Fig.13A) is 7500 calibrated units. 
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However, the reliability of that value is limited because of the few data gathered in long 
incubation intervals. Hexyl-ALA induced a three-fold higher fluorescence intensity 
compared to 5-ALA in the same through timely separate experimental setting. The optimal 
time intervals did not differ significantly between hexyl-ALA and 5-ALA thermogel. The 
averaged tumor selectivities for hexyl-ALA and 5-ALA measured as ratio of CIN versus 
normal epithelium were the same with 1.6. Therefore, hexyl-ALA seems superior 
compared to 5-ALA and may be recommended for the PDT of CIN lesions. The ratio of 
CIN versus normal epithelium is an important parameter for fluorescence diagnosis. For 
photodynamic therapy, however, a maximum fluorescence intensity seems to be of at least 
equal importance. If a high fluorescence intensity can be achieved while having a high 
tumor selectivity, the treatment effect may be restricted to lesional areas only. Otherwise, 
the illumination has to be restricted to CIN areas only in order to avoid side effects in 




Tab. 2. Comparison of PPIX fluorescence with 5-ALA and hexyl-ALA  








Ratio of fluorescence 





Pahernik et al. applied topically 3% ALA solution on CIN lesions. Four hours later, 
fluorescence intensities in tumors were significantly exceeding normal surrounding host 
tissue, but the quantification of ALA induced fluorescence as a function of penetration 
depth revealed that fluorescence intensity was heterogeneous in CIN tissue (Pahernik et al. 
1998). It is important to note that PDT may lead to ineffective elimination of dysplastic 
cells because of a heterogeneous accumulation of PPIX. However, topographic 
fluorescence microscopy showed a more homogenous distribution of PPIX fluorescence in 
dyslastic tissue in our hexyl-ALA study (data not shown). Compared to Pahernik’s study, 
hexyl-ALA could lead to a more homogenous distribution of PPIX fluorescence in 
dysplastic epithelium. This is of major importance for PDT as homogenous PPIX 
fluorescence facilitates a more effective elimination of premalignant cells.  
 
Topographical fluorescence assessment by microscopy showed that maximum intensity 
could generally be detected in the lower layer of the epithelium, consisting of basal and 
parabasal cells, and gradually declined from the basal membrane to the surface of the 
epithelium. This may be explained by the fact that the highest mitotic activity is being 
found in the basal and parabasal cells, which may lead to an accelerated conversion rate of 
hexyl-ALA to PPIX. As opposed to the proliferative basal cells, the intermediate and 
superficial cells are characteristic for cell differentiation. This has been demonstrated by 
various virological and molecular cell studies (Howley et al, 1990; zur Hausen, 1996). It 
would be advantageous to have an improved photodynamic treatment effect in the higher 




Our findings suggest that hexyl-ALA with Lutrol F-127 thermolabile gel as a vehicle 
seems to be a promising molecule for fluorescence diagnosis and treatment of CIN lesions. 
Another relevant factor contributing to a more homogeneous distribution of PPIX may be 
the use of Lutrol F-127 thermolabile gel which yields a more stable presence of 
hexyl-ALA in contact to the cervical surface. This effect has been already demonstrated for 
the topical administration of 5-ALA thermogel (Andikyan et al, 2004) when compared to 
the results by Pahernik et al.(Pahernik et al, 1998). Whether the use of hexyl-ALA 


















Photodynamic therapy (PDT) following topical application of 5-aminolevulinic acid (ALA) 
is increasingly employed for several types of malignancies. Although 5-ALA mediated 
fluorescence has been proven to be effective in diagnosis and treatment of cervical 
intraepithelial neoplasia (CIN), results remain contradictory most likely attributed to the 
difficult precervical application. In order to investigate the pharmacokinetics and 
selectivity of ALA induced porphyrin fluorescence in CIN lesions, 24 non-pregnant 
women with CIN were studied. Prior to surgical conization, hexyl-ALA-thermogel in 
concentrations of 4mM (12 Patients) and 10mM (12 Patients) was applied to the cervix for 
5 to 720 minutes. The fluorescence pattern was quantified by fluorescence microscopy and 
digital image analysis from cryosections. The results showed that hexyl-ALA-induced 
porphyrin fluorescence was stable and higher after application of 10mM hexyl-ALA. We 
observed a higher porphyrin fluorescence intensity within the CIN lesions (2342 ± 381c.u.) 
as compared to normal adjacent epithelium (1484 ± 263 c.u.). This difference was 
statistically significant (p<0,05). 180 to 540 minutes after application porphyrin 
fluorescence in dysplastic epithelium reached a maximal intensity. Tumor selectivity was 
highest in CIN with average tumor to normal tissue ratio of 1.6. Comparing the mean 
fluorescence intensity of high and low grade CIN no statistical difference could be found. 
Topographical fluorescence assessment by microscopy showed that maximum intensity 
could generally be detected in the lower layer of the epithelium, consisting of basal and 
parabasal cells, and gradually declined from the basal membrane to the surface of the 
epithelium. 
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Compared to studies using 5-ALA, hexyl-ALA leads to a much stronger PPIX 
fluorescence in dysplastic epithelium and a similar tumor selectivity. Based on these 
results, hexyl-ALA dissolved in Lutrol F-127 thermolabile gel seems to be a promising 
form for the administration. We recommend the topical application of 10mM of 
























Die photodynamische Therapie (PDT) nach topischer Applikation von 
5-Aminolävulinsäure (5-ALA) findet zunehmenden Einsatz bei verschiedenen 
Tumorentitäten. Obgleich einige Studien gute Resultate mit 5-ALA in der Diagnostik und 
Behandlung von zervikalen intraepitheliale Neoplasie (CIN) aufweisen, bleiben insgesamt 
die Ergebnisse widersprüchlich. Dies ist am ehesten auf das Problem der schwierigen 
präzervikalen Applikation zurückzuführen. Zur Erforschung der Pharmakokinetik und der 
Selektivität von ALA induzierter Porphyrinfluoreszenz in CIN Läsionen wurden 24 
nichtschwangere Frauen in diese ex vivo Studie aufgenommen. Vor der geplanten 
Konisation erfolgte die topische Applikation von Hexyl-ALA-Thermogel in einer 
Konzentration von 4 mM (12 Patientinnen) und 10 mM (12 Patientinnen) vor die Cervix 
uteri mit einem Applikationsintervall von 5 bis 720 Minuten. Die Porphyrinfluoreszenz 
wurde quantifiziert mittels Fluoreszenzmikroskopie und digitaler Bildanalyse von 
Gefrierschnitten. Die Ergebnisse zeigen, dass nach Illumination (Wellenlänge 370-430nm) 
eine höhere Porphyrinfluoreszenz bei 10 mM gegenüber 4 mM Hexyl-ALA erzielt wurde. 
In CIN-Läsionen wurde eine höhere Porphyrinfluoreszenzintensität gemessen (2342 ± 381 
kal. E.) als im benachbarten normalen Epithel (1484 ± 263 kal.E.). Dieser Unterschied war 
statistisch signifikant (p < 0,05). 180 bis 540 Minuten nach topischer Applikation erzielte 
die Porphyrinfluoreszenz im dysplastischen Epithel eine maximale Intensität. Die höchste 
Tumorselektivität wurde in CIN-Läsionen mit einer durchschnittlichen 
Tumor-Normalgewebe-Ratio von 1,6 erzielt. Es fand sich kein statistisch signifikanter 
Unterschied zwischen der mittleren Fluoreszenzintensität von hochgradiger im Vergleich 
zu geringgradiger CIN. In der topografischen Fluoreszenzmikroskopie war jedoch die 
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maximale Fluoreszenzintensität in den proliferativen Basal-und Parabasalzellschichten am 
höchsten nachweisbar und fiel kontinuierlich zu den oberen Zellagen ab. 
 
Verglichen mit Studien, die 5-ALA als Photosensibilisator verwendet haben, erzielte 
Hexyl-ALA induziertes Porphyrin eine deutlich höhere Fluoreszenzintensität im 
dysplastischen Epithel bei vergleichbarer Tumorselektivität. Deshalb empfehlen wir 
Hexyl-ALA Thermogel in einer Konzentration von 10 mM und einer Applikationszeit von 
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1.2 Titel des Forschungsvorhabens:  
 
Klinische Phase I - Studie: Pharmakokinetische, fluoreszenzmikroskopische Studie 
mit Videoimaging zur Gewebeaufnahme und –verteilung von 
Hexyl-Aminolaevulinsäure  bei zervikaler intraepithelialer Neoplasie (CIN 1-3) 
 
 
1.3 Ausbildungsdaten und Prüferfahrungen des Antragstellers: 
 
! Facharzt und Oberarzt der Frauenklinik Großhadern, München 
! Curriculum vitae mit Publikationsverzeichnis zu diesem Gebiet anbei 
! Prüferfahrung des Antragstellers: 
 
• Klinische Phase 2 - Studie: MX6-16:  MX6 in Prentif vs. Femcap Kombination bei Patientinnen 
mit hochgradiger intraepithelialer Neoplasie (CIN 2/3): Leiter der Klinischen Prüfung für 
Deutschland 
• Randomisierte, plazebokontrollierte klinische Studie der ersten Anwendung von HPV 16 L1E7 
CVLP-Impfung bei Zervixdysplasie (CIN 2/3) 
• Multizentrische, offene klinische Studie zu Imiquimod bei Genitalwarzen (IMIQ 1294), Firma 3M 
Medica (1997) 
• Multizentrische klinische Studie zur adjuvanten Therapie mit Aldara 5% nach Laserablation bei 
Kondylomen, Firma 3M Medica (1998) 
• Multizentrische Studie (Phase II) „Photodynamische Lasertherapie von Hautmetastasen des 
Mammakarzinoms mit SnET2“, Pharmacia (1996) 
 
 
1.4 Studiendesign: Monozentrische, klinische Phase I Studie 
1.5 Ärztlicher Leiter der Studie 
 
PD Dr. med. Peter Hillemanns, Oberarzt 
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1.6 Finanzierung des Forschungsvorhabens durch 
 
Das vorliegende Studienprotokoll entspricht einer monozentrischen Phase I Prüfung. Teilfinanzierung 
durch Fa. Photocure ASA, Hoffsveien 48, 0377 Oslo.  
 
Hexyl-Aminolävulinsäure wird von der Firma Photocure, Norwegen, zur Verfügung gestellt. 
 
Die Patientendokumentation wird vom Antragsteller durchgeführt. 
 
  
1.7 Abgeschlossener Versicherungsschutz für Probanden und 
Patientinnen 
 
Patientenversicherung gemäß § 40, 41 wurde bei der Allianz unter folgender 
Versicherungspolicennummer abgeschlossen: ? 
 
1.8 Erklärung  der berücksichtigen Grundsätze der Deklaration von 
Helsinki liegt bei. 
 
1.9 Erklärung über die Einhaltung der Bestimmungen des 
Arzneimittelgesetzes 
 
liegt bei: Die Vorschriften des AMG (§ 40, 41 und 67 AMG) werden eingehalten werden. 
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2. Spezielle Angaben zum Forschungsvorhaben 
 
2.1 Fragestellung (Ziel der Studie, Grundlagen, Bedeutung) 
 
Ziele der Studie sind  
1. Untersuchung der Aufnahme von Hexyl-Aminolaevulinsäure in zervikale 
intraepitheliale Neoplasien zur Prüfung der Eignung von 
Hexyl-Aminolävulinsäure zur Behandlung dieser Neoplasien mit 
Photodynamischer Therapie 
2. Ermittlung der günstigsten Anwendungsdauer und Konzentration von 




Der Gebärmutterhalskrebs ist weltweit gesehen die zweithäufigste Krebserkrankung der 
Frau (WHO 1990). Er entsteht über seine Präkanzerose, die zervikale intraepitheliale Neo-
plasie (CIN). Diese verläuft über drei Schweregrade, CIN 1 bis CIN 3, bevor sie mit einer 
Latenz von 10 Jahren und mehr in das invasive Plattenepithelkarzinom übergehen kann. Die 
Prävalenz der CIN zeigte in Westeuropa und den USA eine ständige Zunahme in den letzten 
zwei Dekaden und liegt bei ca. 3-5%. Es sind vorwiegend Frauen im reproduktiven Alter 
zwischen 25 und 40 Jahren betroffen. Die Krebsvorsorge in der westlichen Welt - mit 
zytologischen Kontrollen im Stadium CIN 1 und 2 (Pap III D) und chirurgischer Therapie im 
Stadium CIN 3 (Pap IVa)  - bewirkte einen deutlichen Rückgang der Zervixkarzinom-
mortalität um ca. 40%. 
Die Infektion mit bestimmten Typen von Humanen Papillomviren (HPV) stellt den 
wesentlichen ursächlichen Faktor in der Entwicklung des Gebärmutterhalskrebses dar. In 
einer weltweiten Untersuchung an fast 1000 Zervixkarzinomen konnte in 99,7% HPV DNA 
mittels Polymerasekettenreaktion (PCR) nachgewiesen werden. Angesichts dieser Daten 
muss auch in einem vergleichbar hohen Prozentsatz die Prävalenz von HPV bei den 
Dysplasien angesetzt werden. In klinischen Studien liegt der Nachweis von HPV bei CIN 
2/3 in Abhängigkeit vom Testverfahren bei 85-100%. Bei gesunden Frauen liegt die 
Prävalenz altersabhängig zwischen 7-20%. 
 
Natürlicher Verlauf: Ungefähr 15% bis 20% der unbehandelten Dysplasien der Portio uteri 
(CIN 1-2) gehen in eine schwere Dysplasie über und ungefähr 5 bis 10% in ein invasives 
Zervixkarzinom nach einem Intervall von 10-20 Jahren. Die mittlere Remissionsrate der 
CIN 1-2 liegt bei ca. 30-50% und rechtfertigt bei Erstdiagnose das kontrollierende Zuwarten 
über einen Zeitraum von ein bis zwei Jahren. Während dieses Zeitraums müssen die 
Patientinnen 3-6 monatlich gynäkologisch untersucht werden mit Entnahme von Zytologie, 
Kolposkopie (Lupenbetrachtung der Zervix) und evtl. gezielten Knipsbiopsien der Portio 
uteri bzw. endozervikale Curettage. Diese engmaschigen Kontrollen stellen für die Patientin 
häufig auch eine erhebliche psychische Belastung dar. Bei der schwergradigen Dysplasie 
(CIN 3) ist in 30-50% mit einer Progression zum invasiven Karzinom zu rechnen. In dem 
Stadium CIN 3 wird die chirurgische Therapie empfohlen. Allerdings nicht in der 
Schwangerschaft. Bei CIN 3 in graviditate wird unter 2-monatigen Kontrollen die Geburt 
abgewartet und erst 2-3 Monate postpartal die Therapie durchgeführt. 
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Therapie: Bei Persistenz oder Progression der CIN ist eine Behandlung indiziert. Die im 
deutschen Sprachraum vorherrschende Technik zur Behandlung der CIN ist die klassische 
Messerkonisation. Mehrere Studien konnten jedoch belegen, dass diese Methode mit einem 
statistisch signifikant erhöhten Risiko für Zervixinsuffizienz und Frühgeburtlichkeit 
einhergeht. Ein weiteres Problem ist die erhöhte perioperative Blutungsrate. Diese Nachteile 
weisen destruierende Methoden wie CO2-Lasertherapie, Kryotherapie oder Kauterisation 
nicht auf. Diese Verfahren konnten sich allerdings nicht etablieren. 
Mit photodynamischer Therapie unter Verwendung von 5-Aminolaevulinsäure können 
prinzipiell Dysplasien mit einer begrenzten Dicke, wie bei den zervikalen Dysplasien 
anzutreffen, behandelt werden. Die Wirksamkeit dieser Therapie für zervikale Dysplasien 
ist zu prüfen. Es ist eine sehr grosse Akzeptanz seitens unserer Patientinnen zu erwarten, da 
die bisherige Alternative allein ein chirurgisches Verfahren mit Destruktion der Portio uteri 
darstellt. 
 
Studienpräparat: Hierbei handelt es sich um eine  4 mM bzw. 10 mM  Lösung von 
Hexyl-Aminolaevulinsäure. Hexyl-Aminolävulinsäure ist ein Ester der 
5-Aminolävulinsäure (5-ALA), das als hydrophile Substanz häufig nur in oberflächliche 
Zellschichten aufgenommen wird und sich inhomogen verteilt. Hexyl-Aminolävulinsäure 
ist wesentlich lipophiler und führt zu einer bis zu 100-fach höheren Konzentration des 
Photosensibilisators Protoporphyrin IX, der aus ALA gebildet wird. Intrazellulär wird die 
Esterbindung gespalten, die Wirksubstanz ist ALA. Bei über 250 Patienten wurden bereits 4 
– 16 mM Lösungen von Hexyl-ALA in die Blase instilliert  zur Fluoreszenz-Zystoskopie, 
ohne daß es dabei zu Nebenwirkungen kam. Entsprechende klinische Erfahrungen liegen in 
der Klinik für Urologie der LMU (Direktor: Prof. Dr. A. Hofstetter) vor. Nach unseren in 
vitro Daten liegt auch ein weiterer Vorteil in der kurzen Konversionszeit von H-ALA zu 
Protoporphyrin IX (W. Xiang, Photochem Photobiol 2001). 
 
 
Bisherige Ergebnisse:  Es ist seit längerem bekannt, dass Photodynamische Therapie (PDT) mit ALA 
die Dysplasien zur Abheilung bringen kann, z.B. im Ösophagus und im Bereich der Vulva. Die Eignung 
von PDT mit ALA wurde auch für zervikale Dysplasien untersucht. In einer Studie des Antragstellers 
(Hillemanns et al., 1999, Int.J.Cancer 81, 34-38) mit Anwendung einer flüssigen ALA-Präparation und 
Zervixkappe wurde gefunden, dass zervikale Dysplasien deutlich verkleinert, aber nicht immer 
eliminiert werden konnten. Es stellt sich die Frage, ob mit einer veränderten Pharmakokinetik durch 
Veresterung von ALA mit eventuell höheren Gewebekonzentration von 5-ALA ein größerer 
therapeutischer Effekt zu erreichen ist. Für Zellkulturen von Cervix-Karzinom-Zellen wurde eine 
beschleunigte Aufnahme in die Zelle bereits nachgewiesen (Xiang W., Hillemanns P. et al. ). Die 
Methodik zur Untersuchung der ALA-Gewebeaufnahme, wie z.B. die für die vorliegende Studie 
vorgesehene Fluoreszenzmikroskopie von entnommenenem Gewebe, ist beim Antragsteller etabliert 
(Pahernik et al., 1998, Int.J.Cancer 78, 310-314). Eine ähnliche Studie wie diese geplante Studie wird 
derzeit mit dem Präparat 5-Aminolävulinsäure in Verbindung mit einer Transportersubstanz 










Es handelt sich um eine prospektive Studie, die die Sicherheit und Pharmakokinetik von 
verschiedenen Konzentrationen and Applikationszeiten von Hexyl-ALA bei Patientinnen 
mit cervikaler intraepithelialer Neoplasie beurteilt. Die Routinediagnostik mit Kolposkopie, 
Zytologie, HPV-DNA Test und kolposkopisch gezielter Knipsbiopsie für die Histologie 
wird vor der Studien-Fluoreszenzdiagnostik durchgeführt.  
Hexyl-ALA wird als eine Lösung in Konzentrationen von 4mM und 10mM aufgetragen, 
beginnend mit kurzen Inkubationszeiten von 5 min, 10 min, 30 min, 60 min und 100 min – in 
Abhängigkeit vom schwer exakt planbaren Operationszeitpunkt (Logistik. Narkose etc.). 
Nach Vorlage von in vitro Daten für das Zervixepithel scheinen kurze Inkubationsintervalle 
ausreichend zu sein. Im Rahmen der klinisch indizierten Konisation erfolgt präoperativ ein 
Fluoreszenz-Imaging. Am entnommenen Konisat wird dann neben der Routinehistologie die 
Fluoreszenzmikroskopie (entspr. der im Hause erfolgten Studie von Pahernik et al., Int. 
Journal of Cancer, 78:310, 1998) durchgeführt. Anhand der fluoreszenzmikroskopischen 
Daten sind längere Inkubationszeiträume gegebenenfalls notwendig. 
 
2.4 Diskussion der ethisch-rechtlich relevanten Probleme des 
Studiendesigns: 
 
Die vorliegende Studie soll mit Patientinnen durchgeführt werden, für die auf Grund  
etablierter, durch die vorliegende Studie nicht beeinflusster Kriterien eine Konisation zur 
Therapie von zervikalen Dysplasien vorgesehen ist. Die vorliegende Studie beinhaltet keine 
Umstände, auf Grund derer eine relevante Beeinflussung der geplanten Konisation 
anzunehmen wäre. 
Es ist weiterhin nicht anzunehmen, dass die geplante Anwendung von Hexyl-ALA zu 
Unverträglichkeitserscheinungen oder Beschwerden führen wird, da keine 
Photodynamische Therapie stattfinden soll, die durch die dabei stattfindende Anwendung 
energiereichen Lichts erst relevante Wirkungen von Hexyl-ALA auf das Gewebe erzeugen 
würde. Die lokale Verträglichkeit von 5-ALA ohne Verbindung mit PDT ist durch 
toxikologische Untersuchungen etabliert. Methyl-ALA, ein weiteres Ester-Derivat  von 
5-ALA ist von der Europäischen Kommission zugelassen. 
Von der hier geplanten lokalen Anwendung von Hexyl-ALA in einem kleinen Areal ist keine relevante 
systemische Resorption zu erwarten. Entsprechend sind keine Nebenwirkungen durch Verteilung in 
andere Gewebe zu erwarten, wie beispielsweise Sensibilisierung der Haut gegenüber 
Sonneneinstrahlung, wie sie bei systemischer Gabe von ALA-Derivaten in zeitlich begrenztem 
Ausmaße vorkommen kann. Eine ähnliche Studie wie diese geplante Studie wird derzeit mit dem 
Präparat 5-Aminolävulinsäure in Verbindung mit einer Transportersubstanz „Thermogel“ zur 
Optimierung der lokalen Applikationstechnik (EK Projekt 127/01 und 128/01) durchgeführt.  
 
 
2.5 Zustimmungsfähigkeit – mutmasslicher Wille der Patientin. 
In dieser Studie werden nur erwachsene und zustimmungsfähige Patientinnen 
eingeschlossen. 
 
2.6 Allfällige Honorierung von Probanden und Patienten. 
Es ist keine Honorierung der Patientinnen vorgesehen. 
 
 





! Histologisch nachgewiesene CIN 1 bis 3 
! Kolposkopie: Transformationszone vollständig einsehbar   
! Zytologie: Pap-Resultate vereinbar mit CIN 1-3 (Pap IIID bis IVb) 
! Verwendung einer zuverlässigen Verhütungsmethode (Verhütungsmittel in  
oraler, injizierter oder implantierter Form) falls Patientin vor der Menopause steht, 
ihre Postmenopause noch keine 2 Jahre her ist oder sie nicht operativ sterilisiert ist.   




! Nicht volljährig 
! Entfernung aller CIN 1-3 Läsionen durch Screening-Biopsie (nachgewiesen durch 
entsprechende Kolpophotographien) 
! Schwangerschaft oder Laktation, positiver Urin-Schwangerschaftstest bei der 
Screeninguntersuchung (Test notwendig bei nicht sterilisierten und prä- und 
perimenopausalen Patientinnen) 
! Toxisches Schock-Syndrom, bekannte Überempfindlichkeit auf Hexyl-ALA  
! Entzündungen in Gebärmutter oder Vagina mit klinischen Symptomen 
! Menstruation hat begonnen oder wird innerhalb von zwei Tagen nach Studieneintritt 
erwartet. 
! Geburt innerhalb von zehn Wochen vor Studieneintritt oder Fehlgeburt innerhalb 
von sechs Wochen vor Studieneintritt. 
! Verwendung eines Intrauterinpessars, der Patientin im gebärfähigen Alter, die kein 
anderes Verhütungsmittel nimmt bzw. nehmen kann. 
! Klinisch bedeutsame abnorme Laborbefunde in Routineblutabnahme: 
" --Transaminasen  > 2fache normale Obergrenze 
" --Alkalische Phosphatase  > 2fache normale Obergrenze 
" --Bilirubin, gesamt > 2,0 mg/100 ml 
" --Kreatinin > 2,0 mg/100 ml 
" --Glucose > 180 mg/100 ml 
 
Auswertung: Die Studiendaten inklusive Fotografien der Zervix, histologische und zytologische 
Ergebnisse sowie HPV-Resultate werden beim ärztlichen Leiter der Studie  ausgewertet. 
 
Nachkontrollen nach der Studie : 
Wie an unserer Klinik üblich, werden  Patientinnen mit einer Dysplasie oder im Z. n. Konisation alle 
3-6 Monate zur Beobachtung einbestellt.   
 
2.8  Aufklärungsschreiben und Einverständniserklärung (Informed consent) 
liegt anbei. 
 
2.9  Vertrauensschutz, Datenschutz liegt anbei 
2.10  Änderungen des Studienprotokolls werden der Ethikkommission mitgeteilt. 
2.11 Aufwandsentschädigung keine 
 
